Sleep Disorder and Cardiovascular Risk Factors among Patients with Type 2 Diabetes Mellitus

Unjin Shim, Hyejin Lee, Jee-Young Oh, and Yeon-Ah Sung

Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea

Background/Aims: Sleep disorder (SD) is associated with an increased risk of cardiovascular disease and is more prevalent among individuals with type 2 diabetes mellitus. These health problems not only frequently coexist but also exacerbate each other. We conducted a cross-sectional study to estimate the prevalence of SD among diabetic patients and to investigate the relationship between SD and cardiovascular risk among these patients.

Methods: We recruited 784 patients with type 2 diabetes and conducted a self-administered questionnaire. We assessed sleep quality using the Pittsburgh Sleep Quality Index and the risk of obstructive sleep apnea (OSA) using the Berlin Questionnaire. Additional information included blood pressure and metabolic profiles.

Results: Of the 784 diabetic patients, 301 (38.4%) patients had poor sleep quality, and 124 (15.8%) were at high risk for OSA. Patients at increased risk for OSA were more obese; they also had higher blood pressure, fasting plasma insulin levels, insulin resistance assessed by homeostasis model assessment (HOMA-IR), and serum triglycerides levels ($p < 0.05$). The frequency of risk for OSA was higher among obese patients compared with non-obese patients (34.8% vs. 9.4%, $p < 0.05$). Logistic regression analysis revealed that male sex and bone mass index were independent predictors of risk for OSA.

Conclusions: SD was prevalent among type 2 diabetic patients, and OSA could aggravate their risk for cardiovascular disease. Clinical treatment of these patients should include evaluation and intervention for SD.

Keywords: Cardiovascular diseases; Sleep apnea, obstructive; Diabetes mellitus, type 2

INTRODUCTION

Sleep disorder (SD) is a common chronic illness characterized by repetitive episodes of partial or complete cessation of breathing during sleep, which may affect up to 17% of middle-aged adults [1]. Chronic sleep fragmentation, sleep deprivation, and intermittent nocturnal hypoxemia associated with SD have been implicated in metabolic dysfunction, including altered glucose metabolism and adverse cardiovascular complications [2,3]. Common antecedent risks such as obesity, hypertension, endothelial dysfunction, inflammatory state, and oxidative stress appear among patients with diabetes mellitus and patients with SD. The association between diabetes mellitus and SD and its precise mechanism are not well understood. It is likely that chronic intermittent hypoxia and sleep fragmentation lead to pathogenic factors such as increased sympathetic activity, dysregulation of the hypothalamus-pituitary-adrenal axis, and activation of inflammatory pathways, resulting in abnormal glucose metabolism.
Large population studies have shown that SD is an independent risk factor for hypertension, cardiovascular disease (CVD) [4-8], and impaired glucose metabolism [9]. Self-reported history of snoring, a common symptom of SD, is independently associated with impaired glucose tolerance and type 2 diabetes mellitus (T2DM) [10,11].

Cross-sectional estimates from population studies have suggested that up to 40% of patients with obstructive sleep apnea (OSA) have T2DM [12,13]. Among patients who are known to have T2DM, the prevalence of OSA may be up to 23% [14], and the prevalence of some form of SD may be as high as 58% [15]. However, scanty documentation is available about the prevalence of SD among Asians. A community study of SD among middle-aged Chinese men and women in Hong Kong revealed 9% and 3.7% prevalence rates for SD and 4% and 2.1% for symptomatic OSA [16,17]. Because only limited studies have focused on the prevalence of SD in T2DM, especially among Asians, the goal of this study was to estimate the prevalence of SD among Korean diabetic patients and determine the association of CVD among these patients.

**METHODS**

**Subjects**

We consecutively recruited 784 patients with T2DM who attended the outpatient department of endocrinology at Ewha Womans University Hospital from January 2008 through December 2008. None of these patients used insulin injection or medications that would affect sleep, and none had serum creatinine levels greater than 1.4 mg/dL, serum transaminases levels more than three times the upper limit of normal value, severe painful peripheral neuropathy, and alcohol dependency. The Institutional Review Board of Ewha Womans University Mokdong Hospital approved this study. Written informed consent was obtained from each subject. Degree of obesity was classified based on the results of an Asia-Pacific study [18]: non-obese patients had a body mass index (BMI) < 25 kg/m² and obese patients had a BMI ≥ 25 kg/m².

**Survey assessment of sleep quality and risk for obstructive sleep apnea**

Sleep quality was assessed using a self-administered questionnaire. The Pittsburgh Sleep Quality Index (SQI) was used to evaluate sleep quality, and the Berlin Questionnaire (BQ) was used to evaluate risk for OSA. The SQI assesses sleep quality over the preceding month and differentiates ‘good’ sleepers from ‘poor’ sleepers [19]. Questionnaire responses involve seven components; each component is scored from 0 to 3, where a score of 3 represents the negative extreme. Component scores are summed to provide the SQI global score (range, 0 to 21); scores > 5 identify ‘poor’ sleepers [19].

The BQ includes five items on snoring (category 1, items 1-5), three items on daytime somnolence (category 2, items 6-8), and one item on the history of hypertension (category 3, item 9). The questionnaire also includes information about age, gender, height, and weight [20]. The overall score is based on the patient’s responses to each of the three categories. The snoring or daytime somnolence categories are positive if responses indicate persistent symptoms (> 3 to 4 times a week) on the questionnaire items. A positive score for the third category requires a history of hypertension or a BMI ≥ 25 kg/m². High risk for OSA is defined as a positive score for two or more of the three categories [21].

**Anthropometric measurements and baseline sampling**

The height and weight of each patient was measured, and BMI was calculated as body weight in kilograms divided by the square of height in meters (kg/m²). Blood pressure (BP) was measured once for each patient in the supine position with a mercury sphygmomanometer; systolic BP and diastolic BP were measured to the nearest 2 mmHg at Korotkoff sounds I and IV, respectively.

Venous blood was drawn from each patient after an overnight fast to obtain baseline measurements of glucose, HbA₁c, total cholesterol, high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG). Plasma glucose was measured using the glucose oxidase method (Beckman Model Glucose Analyzer 2, Brea, CA, USA). Total cholesterol (TC), HDL-C, and TG were measured by enzymatic methods using a Hitachi 7150 autoanalyzer (Hitachi, Tokyo, Japan). LDL cholesterol (LDL-C) was calculated as follows: TC (mg/dL) - HDL-C (mg/dL) - TG/5 (mg/dL).

**Statistical analysis**

Data management and statistical analysis was conducted...
using SPSS version 16 (SPSS Inc., Chicago, IL, USA). The normality of distributions of the variables was analyzed using the Kolmogorov-Smirnov test. Data are expressed as means ± SD. Because TG and HDL-C exhibited skewed distribution, p values were based on logarithmic data, but mean values for untransformed data are presented.

Continuous variables were compared between subjects at high risk and those at low risk for OSA using an independent t test and analysis of covariance (ANCOVA). The χ² test was used to assess differences in the frequency of sleep disturbance in each age group and sex. A logistic regression analysis was performed to determine which variables predicted high risk for OSA. All p values were two-tailed, and statistical significance was defined as p < 0.05.

**RESULTS**

Table 1 lists the clinical and biochemical characteristics of all participants. The mean age was 54 ± 12 years, and 395 (50.4%) participants were male. The mean BMI value was 24.8 ± 3.3 kg/m², mean duration of diabetes was 9 ± 7 years, and mean baseline HbA1c was 7.5 ± 1.4%.

| Characteristics                  | Values |
|----------------------------------|--------|
| Age, yr                          | 54 ± 12 (15-86) |
| Sex                              |        |
| Male                             | 395 (50.4) |
| Female                           | 389 (49.6) |
| BMI, kg/m²                       | 24.8 ± 3.3 |
| < 25                             | 337 (44.5) |
| ≥ 25                             | 420 (55.5) |
| Mean duration of diabetes, yr    | 9 ± 7  |
| Systolic BP, mmHg                | 128 ± 15 |
| Diastolic BP, mmHg               | 75 ± 10  |
| HbA1c, %                         | 7.5 ± 1.4 |
| Fasting plasma glucose, mg/dL    | 132 ± 48 |
| Total cholesterol, mg/dL         | 173 ± 36 |
| HDL-C, mg/dL                     | 51 ± 14  |
| LDL-C, mg/dL                     | 95 ± 35  |
| Triglycerides, mg/dL             | 142 ± 142 |

SQI results revealed poor sleep quality (PSQ) in 301 (38.4%) of 784 diabetic patients, 132 (16.8%) of the 395 male patients, and 169 (21.6%) of the 389 female patients. No significant differences were observed by sex. BQ identified 124 (15.8%) of the 784 patients (44 [5.6%] of the 389 female patients and 80 [10.2%] of the 394 male patients) as being at high risk for OSA, revealing a significantly greater risk among male than female patients (p < 0.05).

Fig. 1 presents the frequency of PSQ by age and sex. PSQ frequency increased for patients aged up to their 50s: 3% in patients in their 30s, 8.1% in patients in their 40s, and 17.2% in patients in their 50s; it then decreased to 13.3% in patients in their 60s and 8.4% in patients in their 70s and older. The frequency of PSQ in patients in their 40s and older was significantly higher than that in patients in their 30s for both sexes (p < 0.05). Similarly, the risk for OSA increased for patients aged up to their 50s: 4.9% in patients in their 30s, 12% in patients in their 40s, and
16.1% in their 50s; it then decreased to 11.6% in patients in their 60s and 5.4% in patients in their 70s and older (Fig. 2). The frequency of risk for OSA was significantly higher among patients in their 40s, 50s, and 60s than among those in their 30s ($p < 0.05$). The frequency of risk for OSA was significantly higher for males than females among patients in their 40s (17.4% vs. 6.6%, $p < 0.05$) and in their 50s (21.5% vs. 10.7%, $p < 0.05$) (Fig. 2). Patients at high risk for OSA had higher BMI, systolic and diastolic blood pressure, fasting plasma insulin, insulin resistance assessed by homeostasis model assessment (HOMA-IR), and triglyceride levels compared with those at low risk (Table 2). Significant differences appeared between the two groups in systolic and diastolic blood pressure and triglyceride levels after adjusting for BMI.

The frequency of risk for OSA was significantly higher among obese patients compared with non-obese patients (34.8% vs. 9.4%, $p < 0.05$). Logistic regression analysis revealed that male sex (odds ratio [OR], 3.14; confidence interval [CI], 1.26 to 7.83; $p < 0.05$) and BMI (OR, 1.25; CI, 1.10 to 1.43; $p < 0.01$) were independent predictors of risk for OSA (Table 3).

### DISCUSSION

This study found that SD was more prevalent in patients with T2DM than in the general population, in which it appears in approximately 9% of women and 24% of men [1]. Of 784 diabetic patients, 301 (38.4%) patients had poor sleep quality according to the SQI, and 124 (15.8%) were at high risk for OSA according to the BQ. Reports from the International Diabetes Federation (IDF) taskforce on epidemiology and prevention [22] have also revealed a high prevalence of SD among patients with T2DM, suggesting a prevalence of SD as high as 58% and a prevalence of OSA as high as 23%. Several prospective studies have reported an association between sleeping disorders and

| Table 2. Comparison of diabetic patients according to risk for OSA |
|---------------------------------------------------------------|
| **High risk for OSA** | **Low risk for OSA** |
| ($n = 124$) | ($n = 660$) |
| Mean age, yr | 55 ± 11 | 55 ± 13 |
| Mean BMI, kg/m² | 27.1 ± 3.5 | 24.4 ± 3.2* |
| Systolic BP, mmHg | 134 ± 15 | 127 ± 15* |
| Diastolic BP, mmHg | 79 ± 9 | 75 ± 10* |
| HbA₁c, % | 7.5 ± 1.2 | 7.5 ± 1.4 |
| FPI, μU/mL | 18.1 ± 19.7 | 9 ± 6.7* |
| HOMA-IR | 6.9 ± 10.7 | 3 ± 2.7* |
| FPG, mg/dL | 134 ± 44 | 132 ± 49 |
| Total cholesterol, mg/dL | 173 ± 49 | 173 ± 33 |
| HDL-C, mg/dL | 49 ± 12 | 51 ± 14 |
| LDL-C, mg/dL | 93 ± 24 | 96 ± 37 |
| Triglycerides, mg/dL | 195 ± 97 | 132 ± 80* |

OSA, obstructive sleep apnea; BMI, body mass index; BP, blood pressure; FPI, fasting plasma insulin; HOMA-IR, insulin resistance assessed by homeostasis model assessment; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

*a $p < 0.05$ vs. high risk.

*b $p < 0.05$ after adjustment for BMI.

| Table 3. Factors associated with the risk for obstructive sleep apnea by logistic regression analysis |
|---------------------------------------------------------------|
| **Odds ratio** | **95% confidence interval** | **p value** |
| Male | 3.14 | 1.26-7.83 | 0.014 |
| BMI | 1.25 | 1.10-1.43 | 0.001 |
| Systolic BP | 1.02 | 0.99-1.05 | 0.258 |
| Diastolic BP | 1.01 | 0.96-1.06 | 0.775 |
| FPI | 1.05 | 0.96-1.14 | 0.273 |
| HOMA-IR | 1.02 | 0.83-1.25 | 0.872 |
| Triglyceride | 1.00 | 0.99-1.00 | 0.797 |

Regression model included age, sex, BMI, systolic and diastolic pressure, HbA₁c, FPI, HOMA-IR, triglyceride, and total, HDL, and LDL cholesterol.

BMI, body mass index; BP, blood pressure; FPI, fasting plasma insulin; HOMA-IR, insulin resistance assessed by homeostasis model assessment; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein.
Our results revealed that obese diabetic patients are at higher risk for OSA, and logistic regression also demonstrated that BMI is an independent predictor of risk for OSA. A recent study of obese men (BMI ≥ 30 kg/m²) without major medical illnesses found that 60% of these men met the criteria for SD, and 27% had OSA [2]. The risk of having moderate to severe OSA over a 4-year period increases six-fold among individuals who gain 10% excess weight [40], suggesting that the high incidence of CV morbidity among patients with OSA is explained by the presence of obesity [41,42]. With the onset of OSA, individuals develop leptin resistance, which in turn contributes to further weight gain [28]. Inflammatory cytokines tumor necrosis factor (TNF)-α and interleukin (IL)-6, which are associated with daytime sleepiness, might also be involved in the causal pathway because they are elevated among obese patients with OSA [43].

Fasting plasma insulin levels and HOMA-IR were higher among patients at high risk for OSA. The mechanism underlying the relationship between SD and insulin resistance can be explained as follows [44]. Hypoxia and hypercapnia caused by sleep-disordered breathing provoke sympathetic nervous activity, releasing epinephrine, norepinephrine, and cortisol [45-47]. Sympathetic hyperactivity and increased catecholamine impair glucose homeostasis and induce insulin resistance by increasing glycogenolysis and gluconeogenesis [48,49]. Repetitive cycles of intermittent hypoxemia followed by re-oxygenation may trigger the formation of reactive oxygen species, eliciting the release of inflammatory cytokines such as TNF-α and IL-6 [50,51]. Inflammatory cytokines play an important role in mediating peripheral insulin resistance by inhibiting glucose uptake by fat and muscle, increasing the level of counter-regulatory hormones and inducing the release of free fatty acids [52,53].

We found a higher frequency of risk for OSA among men, with logistic regression analysis revealing male sex to be an independent predictor. The higher prevalence of risk for OSA among men than women could be related to the greater tendency toward android fat distribution [54] and differences in upper airway muscle function during sleep [54]. Men have a greater increase in airway resistance and greater susceptibility to flow limitation during non-rapid eye movement (NREM) sleep than women do. During NREM sleep, women have a functional advantage over men that is protective against airway collapse, and this
protective mechanism is lost with the transition to REM sleep [54].

This study had several limitations. First, its relatively small sample size limits the generalization of results. Large-scale long-term research will be needed in the future. Second, we did not consider the medications used by patients or the effects of hypoglycemia. We excluded patients who used insulin injection or medications that might affect sleep, but we did not consider hypoglycemic events, which might affect sleep patterns. Finally, the results might be affected by recall bias and the subjective nature of self-reported snoring and OSA. However, self-reported snoring and snoring reported by roommates were reasonably correlated in previous studies [55].

In conclusion, our data suggest that SD is prevalent among type 2 diabetic patients and that individuals at high risk for OSA are also at higher risk for CVD. OSA appears to aggravate the risk of CVD among type 2 diabetic patients. Therefore, early detection and treatment of SD among type 2 diabetic patients is essential to modulate the relationship between SD and risk for CVD.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002;165:1217-1239.
2. Punjabi NM, Sorkin JD, Katzel LI, Goldberg AP, Schwartz AR, Smith PL. Sleep-disordered breathing and insulin resistance in middle-aged and overweight men. Am J Respir Crit Care Med 2002;165:677-682.
3. Vgontzas AN, Bixler EO, Chrousos GP. Metabolic disturbances in obesity versus sleep apnoea: the importance of visceral obesity and insulin resistance. J Intern Med 2003;254:32-44.
4. Punjabi NM, Ahmed MM, Polotsky VY, Beamer BA, O’Donnell CP. Sleep-disordered breathing, glucose intolerance, and insulin resistance. Respir Physiol Neurobiol 2003;136:167-178.
5. Choi KM, Lee JS, Park HS, Baik SH, Choi DS, Kim SM. Relationship between sleep duration and the metabolic syndrome: Korean National Health and Nutrition Survey 2001. Int J Obes (Lond) 2008;32:1091-1097.
6. Punjabi NM, Caffo BS, Goodwin JL, et al. Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med 2009;6:e1000132.
7. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000;342:1378-1384.
8. Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001;163:19-25.
9. Ybarra J, Planas F, Navarro-Lopez F, et al. Association between sleep-disordered breathing, aminoterminal pro-brain natriuretic peptide (NT-proBNP) levels and insulin resistance in morbidly obese young women. Eur J Intern Med 2009;20:174-181.
10. Elmasry A, Janson C, Lindberg E, Gislason T, Tageldin MA, Boman G. The role of habitual snoring and obesity in the development of diabetes: a 10-year follow-up study in a male population. J Intern Med 2000;248:13-20.
11. Al-Delaimy WK, Manson JE, Willett WC, Stampfer MJ, Hu FB. Snoring as a risk factor for type II diabetes mellitus: a prospective study. Am J Epidemiol 2002;155:387-393.
12. Meslier N, Gagnadoux F, Giraud P, et al. Impaired glucose-insulin metabolism in males with obstructive sleep apnoea syndrome. Eur Respir J 2003;22:156-160.
13. Elmasry A, Lindberg E, Berne C, et al. Sleep-disordered breathing and glucose metabolism in hypertensive men: a population-based study. J Intern Med 2001;249:153-161.
14. West SD, Nicoll DJ, Stradling JR. Prevalence of obstructive sleep apnoea in men with type 2 diabetes. Thorax 2006;61:945-950.
15. Resnick HE, Redline S, Shahar E, et al. Diabetes and sleep disturbances: findings from the Sleep Heart Health Study. Diabetes Care 2003;26:702-709.
16. Ip MS, Lam B, Lauder IJ, et al. A community study of sleep-disordered breathing in middle-aged Chinese men in Hong Kong. Chest 2001;119:62-69.
17. Ip MS, Lam B, Tang LC, Lauder IJ, Ip TY, Lam WK. A community study of sleep-disordered breathing in middle-aged Chinese women in Hong Kong: prevalence and gender differences. Chest 2004;125:127-134.
18. Cockram CS. Diabetes mellitus: perspective from the Asia-Pacific region. Diabetes Res Clin Pract 2000;50 Suppl 2:S3-S7.
19. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213.
20. Netzer NC, Strohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med 1999;131:485-491.
21. Ahmadi N, Chung SA, Gibbs A, Shapiro CM. The Berlin
questionnaire for sleep apnea in a sleep clinic population: relationship to polysomnographic measurement of respiratory disturbance. Sleep Breath 2008;12:39-45.

22. Shaw JE, Punjabi NM, Wilding JP, Alberti KG, Zimmet PZ. International Diabetes Federation Taskforce on Epidemiology and Prevention. Sleep-disordered breathing and type 2 diabetes: a report from the International Diabetes Federation Taskforce on Epidemiology and Prevention. Diabetes Res Clin Pract 2008;81:2-12.

23. Ayas NT, White DP, Al-Delaimy WK, et al. A prospective study of self-reported sleep duration and incident diabetes in women. Diabetes Care 2003;26:380-384.

24. Cunha MC, Zanetti ML, Hass VJ. Sleep quality in type 2 diabetes. Rev Lat Am Enfermagem 2008;16:850-855.

25. Nonogaki K. New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia 2000;43:533-549.

26. Yaggi HK, Araujo AB, McKinlay JB. Sleep duration as a risk factor for the development of type 2 diabetes. Diabetes Care 2006;29:657-661.

27. Chaput JP, Despres JP, Bouchard C, Astrup A, Tremblay A. Sleep duration as a risk factor for the development of type 2 diabetes or impaired glucose tolerance: analyses of the Quebec Family Study. Sleep Med 2009;10:994-924.

28. Jean-Louis G, Zizi F, Clark LT, Brown CD, McFarlane SL. Obstructive sleep apnea and cardiovascular disease: role of the metabolic syndrome and its components. J Clin Sleep Med 2008;4:261-272.

29. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 2004;33:283-303.

30. Reaven G, Abbasi F, McLaughlin T. Obesity, insulin resistance, and cardiovascular disease. Recent Prog Horm Res 2004;59:207-223.

31. Marshall NS, Wong KK, Liu PY, Cullen SR, Knuiman MW, Grunstein RR. Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study. Sleep 2008;31:1079-1085.

32. Yumino D, Wang H, Floras JS, et al. Relationship between sleep apnoea and mortality in patients with ischaemic heart failure. Heart 2009;95:819-824.

33. Young T, Finn L, Peppard PE, et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep 2008;31:1071-1078.

34. Kato M, Adachi T, Koshino Y, Somers VK. Obstructive sleep apnea and cardiovascular disease. Circ J 2009;73:1363-1370.

35. Schulz R, Hummel C, Heinemann S, Seeger W, Grimminger F. Serum levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea and severe nighttime hypoaxia. Am J Respir Crit Care Med 2002;165:67-70.

36. Schulz R, Flototto C, Jahn A, et al. Circulating adrenomedullin in obstructive sleep apnoea. J Sleep Res 2006;15:89-95.

37. Riha RL, Brander P, Vennelle M, et al. Tumour necrosis factor-alpha (-308) gene polymorphism in obstructive sleep apnoea-hypoapnoea syndrome. Eur Respir J 2005;26:673-678.

38. Shamsuzzaman AS, Winnicki M, Lanfranchi P, et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002;105:2462-2464.

39. Robinson GV, Peperell JC, Segal HC, Davies RJ, Stradling JR. Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomized controlled trials. Thorax 2004;59:777-782.

40. Makinodan K, Yoshikawa M, Fukuoka A, et al. Effect of serum leptin levels on hypercapnic ventilator response in obstructive sleep apnea. Respiration 2008;75:257-264.

41. Vgontzas AN, Papanicolaou DA, Bixler EO, et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 2000;85:1151-1158.

42. Coughlin SR, Mawdsley L, Mugarza JA, Calverley PM, Wilding JP. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J 2004;25:735-741.

43. Hu FB, Willett WC, Colditz GA, et al. Prospective study of snoring and risk of hypertension in women. Am J Epidemiol 1999;150:806-816.

44. Joo S, Lee S, Choi HA, et al. Habitual snoring is associated with elevated hemoglobin A1c levels in non-obese middle-aged adults. J Sleep Res 2006;15:437-444.

45. Fletcher EC. Sympathetic activity and blood pressure in the sleep apnea syndrome. Respiration 1997;64 Suppl 1:22-28.

46. Fletcher EC. Sympathetic over activity in the etiology of hypertension of obstructive sleep apnea. Sleep 2003;26:15-19.

47. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 1995;95:1897-1904.

48. Hjalmarsen A, Aasebø U, Birkeland K, Sager G, Jorde R. Impaired glucose tolerance in patients with chronic hypoxic pulmonary disease. Diabetes Metab 1996;22:37-42.

49. Marshall S, Garvey WT, Traxinger RR. New insights into the metabolic regulation of insulin action and insulin resistance: role of glucose and amino acids. FASEB J 1991;5:3031-3036.

50. Dyugovskaya L, Lavie P, Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med 2002;165:934-939.

51. Schulz R, Mahmoudi S, Hattar K, et al. Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea: impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med 2000;162(2 Pt 1):366-370.

52. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose
expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91.

53. Stumvoll M, Haring H. Insulin resistance and insulin sensitizers. Horm Res 2001;55 Suppl 2:3-13.

54. O'Connor C, Thornley KS, Hanly PJ. Gender differences in the polysomnographic features of obstructive sleep apnea. Am J Respir Crit Care Med 2000;161:1465-1472.

55. Enright PL, Newman AB, Wahl PW, Manolio TA, Haponik EF, Boyle PJ. Prevalence and correlates of snoring and observed apneas in 5,201 older adults. Sleep 1996;19:531-538.